Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Abemaciclib is an ATP-competitive inhibitor targeting CDK4 and CDK6.
• It has demonstrated antitumor activity in hormone receptor-positive (HR+) metastatic breast cancer.
• Understanding its mechanistic effects is crucial for optimizing treatment strategies.

Purpose of the Study:

• To investigate the mechanistic effects of abemaciclib in vitro and in vivo breast cancer models.
• To elucidate the molecular pathways and cellular responses induced by abemaciclib.
• To evaluate the sustained antitumor effects of abemaciclib monotherapy.

Main Methods:

• Utilized in vitro and in vivo models of estrogen receptor-positive (ER+) breast cancer.
• Assessed effects on Rb phosphorylation, cell cycle arrest (G1), proliferation, and DNA synthesis.
• Evaluated senescence markers (β-galactosidase, senescence-associated heterochromatin foci, FOXM1), apoptosis, and metabolic alterations.
• Tested abemaciclib monotherapy in an ER+ breast cancer xenograft model.

Main Results:

• Abemaciclib treatment decreased Rb phosphorylation, induced G1 arrest, and reduced proliferation in ER+ breast cancer cells.
• Durable inhibition of pRb, TopoIIα expression, and DNA synthesis was observed, persisting after drug removal.
• Abemaciclib induced a senescence response, altered cellular metabolism, and promoted apoptosis.
• Monotherapy with abemaciclib resulted in tumor growth regression in a xenograft model.

Conclusions:

• Abemaciclib functions as a potent CDK4/6 inhibitor, effectively blocking breast cancer cell progression as a single agent.
• Extended abemaciclib treatment leads to sustained antitumor effects via induction of senescence, apoptosis, and metabolic alterations.
• These findings support abemaciclib's role in managing HR+ metastatic breast cancer.